van Wijngaarden, A.P.; Britsch, I.; Peipp, M.; Samplonius, D.F.; Helfrich, W.
CD19-ReTARGTPR: A Novel Fusion Protein for Physiological Engagement of Anti-CMV Cytotoxic T Cells Against CD19-Expressing Malignancies. Cancers 2025, 17, 2300.
https://doi.org/10.3390/cancers17142300
AMA Style
van Wijngaarden AP, Britsch I, Peipp M, Samplonius DF, Helfrich W.
CD19-ReTARGTPR: A Novel Fusion Protein for Physiological Engagement of Anti-CMV Cytotoxic T Cells Against CD19-Expressing Malignancies. Cancers. 2025; 17(14):2300.
https://doi.org/10.3390/cancers17142300
Chicago/Turabian Style
van Wijngaarden, Anne Paulien, Isabel Britsch, Matthias Peipp, Douwe Freerk Samplonius, and Wijnand Helfrich.
2025. "CD19-ReTARGTPR: A Novel Fusion Protein for Physiological Engagement of Anti-CMV Cytotoxic T Cells Against CD19-Expressing Malignancies" Cancers 17, no. 14: 2300.
https://doi.org/10.3390/cancers17142300
APA Style
van Wijngaarden, A. P., Britsch, I., Peipp, M., Samplonius, D. F., & Helfrich, W.
(2025). CD19-ReTARGTPR: A Novel Fusion Protein for Physiological Engagement of Anti-CMV Cytotoxic T Cells Against CD19-Expressing Malignancies. Cancers, 17(14), 2300.
https://doi.org/10.3390/cancers17142300